TZ-2 (Tirz)

TZ-2 — Dual Incretin Receptor Agonist Peptide

TZ-2 is a high-purity research peptide that functions as a dual incretin receptor agonist, simultaneously engaging both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism targets two key metabolic signaling pathways involved in glucose homeostasis and energy regulation.

Mechanism of Action

TZ-2 activates GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon release, while simultaneously stimulating GIP receptors to amplify incretin signaling and improve beta-cell responsiveness. The dual agonism produces complementary metabolic effects: GLP-1 receptor activation slows gastric emptying and modulates appetite signaling, while GIP receptor engagement enhances the insulinotropic response and may influence lipid metabolism in adipose tissue.

Research Applications

• Dual incretin pathway modulation studies
• Glucose homeostasis and insulin secretion research
• GLP-1 and GIP receptor co-activation mechanisms
• Appetite regulation and energy balance investigations
• Comparative studies with single-receptor agonists
• Beta-cell function and pancreatic islet research

Product Specifications

• Quantity: 10mg per vial
• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: Refrigerate after reconstitution
• Testing: USA lab tested, COA available

For research purposes only. Not for human use or consumption.